Citadel Advisors
LPCN icon

Citadel Advisors’s Lipocine LPCN Stock Holding History

Citadel Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
81,221
+52,133
+179% +$125K ﹤0.01% 11984
2026
Q1 		$232K Buy
+29,088
New +$253K ﹤0.01% 11090
2025
Q4 		– Sell
-14,247
Closed -$40.7K – 13486
2025
Q3 		$40.7K Buy
+14,247
New +$43.3K ﹤0.01% 12289
2023
Q2 		– Sell
-5,494
Closed -$29.7K – 14858
2023
Q1 		$29.7K Sell
5,494
-776
-12% -$5.99K ﹤0.01% 12746
2022
Q4 		$40.9K Sell
6,270
-11,107
-64% -$80.9K ﹤0.01% 12381
2022
Q3 		$133K Buy
+17,377
New +$194K ﹤0.01% 10838
2022
Q2 		– Sell
-3,714
Closed -$57.9K – 13589
2022
Q1 		$86K Buy
3,714
+1,620
+77% +$33.9K ﹤0.01% 12419
2021
Q4 		$36K Sell
2,094
-1,178
-36% -$21.9K ﹤0.01% 13409
2021
Q3 		$61K Buy
+3,272
New +$72.2K ﹤0.01% 13255
2021
Q2 		– Sell
-2,457
Closed -$57.8K – 14081
2021
Q1 		$63K Sell
2,457
-1,948
-44% -$56.2K ﹤0.01% 12785
2020
Q4 		$102K Buy
4,405
+3,692
+518% +$88.9K ﹤0.01% 10209
2020
Q3 		$17K Buy
+713
New +$18.9K ﹤0.01% 9886
2020
Q2 		– Sell
-721
Closed -$9.34K – 10208
2020
Q1 		$6K Buy
+721
New +$5.71K ﹤0.01% 9473
2019
Q2 		– Sell
-609
Closed -$24K – 9558
2019
Q1 		$24K Sell
609
-157
-20% -$4.82K ﹤0.01% 9032
2018
Q4 		$17K Buy
+766
New +$17.8K ﹤0.01% 8803
2018
Q3 		– Sell
-964
Closed -$23.7K – 9502
2018
Q2 		$21K Buy
+964
New +$23K ﹤0.01% 8643
2015
Q4 		– Sell
-4,076
Closed -$820K – 8978
2015
Q3 		$820K Buy
+4,076
New +$943K ﹤0.01% 4085

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

Citadel Advisors's LPCN Position: Q2 2026 in Review

Citadel Advisors increased its Lipocine (LPCN) stake by 179% in Q2 2026, buying an estimated $125K and bringing the position to 81,221 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #11984.

Citadel Advisors first reported a position in LPCN in Q3 2015 and has held it in 17 quarters since. The position peaked at $820K in Q3 2015. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Citadel Advisors held 81,221 shares of Lipocine worth $208K as of Q2 2026.
  • Citadel Advisors bought 52,133 Lipocine shares in Q2 2026, an estimated $125K.
  • Lipocine made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11984 holding.
  • Citadel Advisors first reported a position in Lipocine in Q3 2015 and has held it in 17 quarters since.
  • Citadel Advisors's Lipocine position peaked at $820K in Q3 2015.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.